PENTA Foundation

Recent papers from PENTA Foundation

1. Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaborationHIV Medicine · 2026
2. Predictors of HIV reservoir size and decay dynamics in early-treated paediatric infection: a prospective, multicentre longitudinal cohort studyEBioMedicine · 2026
3. Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trialThe Lancet · 2026
4. HIV-1 Drug Resistance in Mother–Infant Pairs in Southern MozambiqueThe Pediatric Infectious Disease Journal · 2026
5. Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trialThe Lancet · 2026
6. Neonatal Unit Colonization Pressure and Acquisition of Extended-Spectrum β-Lactamase Gut ColonizationJAMA Network Open · 2026
7. Network analysis of key constructs supporting screening of at-risk adolescents in the LOOK@ME projectCurrent Psychology · 2026
8. Pharmacokinetic modeling to support WHO-weight band dosing of a new pediatric darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children at least 3 years old and weighing 10 to less than 35 kgJAIDS Journal of Acquired Immune Deficiency Syndromes · 2026
9. Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trialThe Lancet · 2026
10. Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide FumarateClinical Pharmacokinetics · 2026
11. PregInPoxVac maternal protocol: a phase 3 trial evaluating maternal immunogenicity and safety of the MVA-BN vaccine in the Democratic Republic of the CongoBMJ Open · 2026
12. Identifying and Deploying Benchmarks for Clinical Research at SitesTherapeutic Innovation & Regulatory Science · 2026
13. Parental attachment and psychological wellbeing in the Neonatal Intensive Care Unit: what we learned from SARS-CoV-2 pandemicGlobal Pediatrics · 2026
14. Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trialOpen Forum Infectious Diseases · 2026
15. Development and validation of a short form of the Yale Food Addiction Scale 2.0 in adolescents.2026
16. Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trialThe Lancet HIV · 2026
17. Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic reviewBMC Infectious Diseases · 2026
18. Risk of SARS ‐ CoV ‐2 Infection and Hospitalisation in Immunocompromised Children: A Population‐Based Cohort Study in Italy and NorwayActa Paediatrica · 2026
19. Emotion Regulation Strategies and Social Media Addiction: Gender‐Specific Pathways Through Social Anxiety and Depression in YouthHuman Behavior and Emerging Technologies · 2026
20. Harmonizing Case Validation for Vaccine Safety in Real-World Data: The VAC4EU ExperienceClinical Epidemiology · 2026